학술논문

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, December 2023, 24(12):1423-1433)
Subject
Language
English
ISSN
14745488
14702045